CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

PURPOSE: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS: Participants with chronic pain (94% on...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Genet Med
Egile Nagusiak: Smith, D. Max, Weitzel, Kristin W., Elsey, Amanda R., Langaee, Taimour, Gong, Yan, Wake, Dyson T., Duong, Benjamin Q., Hagen, Melanie, Harle, Christopher A., Mercado, Elvira, Nagoshi, Ying, Newsom, Kimberly, Wright, Ashleigh, Rosenberg, Eric I., Starostik, Petr, Clare-Salzler, Michael J., Schmidt, Siegfried O., Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://ncbi.nlm.nih.gov/pubmed/30670877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41436-018-0431-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak